Phenylephrine injection recalled due to lack of sterility assurance
Nephron Sterile Compounding Center is recalling Phenylephrine HCl injection nationwide due to lack of assurance of sterility. Lot PS2008A with expiration 03/07/2023 is affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall addresses lack of sterility assurance in injectable medication. No illnesses or injuries have been reported. The classification meets the severity rubric criterion for high-risk products where injury has not yet been reported.
Plain-English summary
Nephron Sterile Compounding Center LLC is recalling Phenylephrine HCl in 0.9% Sodium Chloride Injection due to lack of assurance of sterility. The product is distributed nationwide as 250 mL single-dose bottles in cartons of 15 (NDC 69374-321-25).
The FDA classified this as a Class II recall. Lot PS2008A, which expires 03/07/2023, affects 10,980 bottles. The recall was issued because sterility could not be confirmed for this lot.
Healthcare providers and facilities in receipt of this medication should verify their inventory against the affected lot number and discontinue use if present.
The recalled product
- Product
- Phenylephrine HCl in 0.9% Sodium Chloride Injection, USP, 50 mg/250 mL (200 mcg/mL), 250 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-321-25.
- Manufacturer
- Nephron Sterile Compounding Center LLC
- Category
- Drug — Injectable / Intravenous
- Hazard
- lack-of-sterility
- contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lots: PS2008A
- Exp. 03/07/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27